PGxKM

The Case of Melanoma

Seven drugs were included in this cases from FDA Table of Pharmacogenomic Biomarkers in Drug Labeling: Binimetinib, Cobimetinib, Dabrafenib, Encorafenib, Nivolumab, Trametinib, Vemurafenib. Most were newly indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by FDA-approved tests in 2018. At last, 4,846 triples were established in the PGxKM of melanoma, including 141 from drug labels and 4,705 drug-drug interactions from RxNorm.

PGxKM included nine groups of pharmacogenomics relationships in this model, which can present more potential information than other relevant data sources such as DrugBank, PharmGKB, CTD and RxNorm.

Visualization of part of the triples are presented on the right side.